Jonathan Marmur, MD, FACC, FRCP

Education and Training:

Position held:

Professor, Interim Chief of Cardiology, Director, Cardiac Catheterization Laboratory, Program Director Interventional Cardiology Fellowship Program

Fellowship:

American Board Certification in Cardiology, March 1990
Certificate of Competence in Cardiology, Royal College of Physicians of Canada, Nov 1988
American Board Certification in Interventional Cardiology, Nov 2000
Certification Board of Cardiovascular Computed Tomography, Dec 2008

Medical School:

Laval University, Quebec City, Canada 1982

Career / Research Interests:

Patents

Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) is an Independent Predictor of All-Cause Mortality, Cardiac Mortality, and Myocardial Infarction. Submitted December 2, 2004 by The Research Foundation of the State University of New York (SUNY). For more information, visit: www.RFSUNY.org.

Past Grants

1. Principal investigator: Jonathan D. Marmur
   • source: Ontario Heart and Stroke Foundation
   • title of project: Biologic Response to Vascular Injury
   • dates of project: 1988-1990
   • total direct cost of project $70,000
2. Principal investigator: Jonathan D. Marmur
   • source: Medical Research Council of Canada Fellowship Award (9211FER-1033-34668)
   • title of project: Molecular Responses to Vascular Injury
   • dates of grant: 1990-1994
   • total direct cost of project $202,000
3. Principal investigator: Jonathan D. Marmur
   • source: NIH/NHLBI (KO8 HL03210-01)
   • title of project: Tissue Factor Regulation In Arterial Injury
   • dates of project: 1994-1999
   • total direct cost of project $436,590
4. Principal investigator: Jonathan D. Marmur
   • source: Novo Nordisc
   • title of project: FFR-rFVII in Patients Undergoing Elective PTCA-ACES
   • dates of project: 1999-2001
   • total direct cost of project $65,750
5. Local (Mt. Sinai Hospital, NY) principal investigator: Jonathan D. Marmur
   • source: Berlex Laboratories
   • title of project: Adenovirus Mediated Human FGF4 Gene Transfer in Patients with Angina Pectoris
   • dates of project: 1998-2001
   • total direct cost of project $155,000
6. Principal investigator: Jonathan D. Marmur
   • source: Pharmacia & Upjohn
   • title of project: Dalteparin Reopro ACT Monitoring (DREAM)
   • dates of project: 2000-2003
   • total direct cost of project $182,000
7. Local (Mt. Sinai Hospital, NY) principal investigator: Jonathan D. Marmur
   • source: Berlex Laboratories
   • title of project: A Multicenter, Randomized Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina
   • dates of project: 2000-2003
   • total direct cost of project $181,000

Current Grants

1. Source: Pfizer, Inc.
   • Title: ACT-guided Titration of Low Molecular Weight Heparin Dosing in Percutaneous Coronary Intervention
   • Period of Support: 2003-present
   • Role: Principal Investigator
   • Total Cost of Project: $600,000
2. Source: National Institutes of Health
   • Grant Number: 1R21HL098661-01
   • Title: Plasma F11R and Cardiovascular Outcomes in Patients with Coronary Artery Disease
   • Period of Support: 03/01/2010 - 02/29/2012
   • Role: Collaborator (Principal Investigator: Dr. Erdal Cavusoglu)
   • Aim: The major aim of this project is to investigate the role of F11R in patients with established coronary artery disease
3. Source: American Heart Association (Founders Affiliate)
   • Grant Number: 10GRNT3700003 (Grant-in-Aid)
   • Title: Endogenous Erythropoietin and Outcome in Coronary Artery Disease
   • Period of Support: 07/01/2010 - 06/30/2013
   • Role: Collaborator (Principal Investigator: Dr. Erdal Cavusoglu)
   • Aim: The major aim of this project is to determine the prognostic significance of erythropoietin in patients with the acute coronary syndromes

• Zhang M, Hou YJ, Cavusoglu E, Lee DC, Steffensen R, Yang L, Bashari D, Villamil J, Moussa M, Fernaine G, Jensenius JC, Marmur JD, Ko W, Shevde K. MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans. Int JCardiol. 2013 Jun 20;166(2):499-504.
• Law S, Panichpisal K, Demede M, John S, Marmur JD, Nath J, Baird AE. ContrastInduced Neurotoxicity following Cardiac Catheterization. Case Rep Med 2012;2012:267860
• Ko W, Tranbaugh R, Marmur JD, Supino PG, Borer JS. Myocardial Revascularization in New York State: Variations in the PCI-to-CABG Ratio and Their Implications. J Am Heart Assoc. 2012 Apr; 1(2):e001446.
• Cavusoglu E, Marmur JD, Hojjati MR, Chopra V, Butala M, Subnani R, Huda MS, Yanamadala S, Ruwende C, Eng C, Pinsky DJ. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am J Med. 2011 Aug;124(8):724-30.
• Azari BM, Marmur JD, Salifu MO, Ehrlich YH, Kornecki E, Babinska A. Transcription and translation of human F11R gene are required for an initial step of atherogenesis induced by inflammatory cytokines. J Transl Med. 2011;9:98.
• Azari BM, Marmur JD, Salifu MO, Cavusoglu E, Ehrlich YH, Kornecki E, Babinska A. Silencing of the F11R gene reveals a role for F11R/JAM-A in the migration of inflamed vascular smooth muscle cells and in atherosclerosis. Atherosclerosis. 2010;212:197-205.
• Cavusoglu E, Ruwende C, Chopra V, Poludasu S, Yanamadala S, Frishman WH, Eng C, Pinsky DJ, Marmur JD. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis. 2010;210:226-31.
• Poludasu S, Cavusoglu E, Khan W, Marmur JD. Neutrophil to lymphocyte ratio as a predictor of long-term mortality in African Americans undergoing percutaneous coronary intervention. Clin Cardiol. 2009;32:E6-E10.
• Marmur JD, Bullock-Palmer RP, Poludasu S, Cavusoglu E. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention. J Invasive Cardiol. 2009;21:653-64.
• Poludasu S, Marmur JD, Weedon J, Khan W, Cavusoglu E. Red cell distribution width (RDW) as a predictor of long-term mortality in patients undergoing percutaneous coronary intervention. Thromb Haemost. 2009;102:581-7.
• Cavusoglu E, Marmur JD, Chhabra S, Chopra V, Eng C, Jiang XC. Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography. Atherosclerosis. 2009;207:261-5.
• Cavusoglu E, Chopra V, Gupta A, Choksi PU, Ruwende C, Yanamadala S, Frishman WH, Pinsky DJ, Marmur JD. Relation of baseline serum potassium levels to angiographic findings in patients with known or suspected coronary artery disease. Am J Hypertens. 2009;22:754-62.
• Poludasu S, Marmur JD, Weedon J, Khan W, Cavusoglu E. Effect of hemoglobin level on long-term all-cause mortality after percutaneous coronary intervention in . Am J Cardiol. 2009;103:1078-82. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Pinsky DJ, Marmur JD. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography. Coron Artery Dis. 2009;20:112-117.
• Marmur JD, Poludasu S, Lazar J, Cavusoglu E. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2009;73:214-221.
• Cavusoglu E, Chopra V, Gupta A, Battala VR, Poludasu S, Eng C, Marmur JD. Relation between red blood cell distribution width (RDW) and all-cause mortality at two years in an unselected population referred for coronary angiography. Int J Cardiol. 2009 Jan 12.